LUNG CANCER

December 6th 2024

In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.

December 5th 2024

Lung cancer innovations are not only extending lives but also enhancing the quality of life for patients, offering renewed hope to millions worldwide.

December 4th 2024

With this approval, zenocutuzumab is the first FDA-approved therapy for patients with NRG1 fusion tumors.

December 4th 2024

The FDA granted breakthrough therapy status to sacituzumab tirumotecan in EGFR-mutated advanced non–small cell lung cancer.